LMLL.F Stock Overview
Pharmadrug Inc. operates as a specialty pharmaceutical company.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Pharmadrug Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.021 |
52 Week High | CA$0.065 |
52 Week Low | CA$0.011 |
Beta | 2.91 |
1 Month Change | -25.69% |
3 Month Change | -28.67% |
1 Year Change | -58.69% |
3 Year Change | -96.18% |
5 Year Change | -98.16% |
Change since IPO | -99.00% |
Recent News & Updates
Recent updates
Shareholder Returns
LMLL.F | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -15.1% | 3.0% | -0.7% |
1Y | -58.7% | 12.5% | 22.8% |
Return vs Industry: LMLL.F underperformed the US Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: LMLL.F underperformed the US Market which returned 22.3% over the past year.
Price Volatility
LMLL.F volatility | |
---|---|
LMLL.F Average Weekly Movement | 29.4% |
Pharmaceuticals Industry Average Movement | 10.0% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 16.7% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LMLL.F's share price has been volatile over the past 3 months.
Volatility Over Time: LMLL.F's weekly volatility (29%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | n/a | Robert Steen | www.pharmadrug.ca |
Pharmadrug Inc. operates as a specialty pharmaceutical company. It focuses on the research, development, and commercialization of controlled-substances and natural medicines, such as psychedelics, cannabis, and naturally-derived approved drugs. It also imports and distributes medical cannabis to pharmacies in Germany and rest of the European Union; and owns and operates Super Smart, an entity building to vertically integrated elevate the use of functional mushrooms and psilocybin mushrooms.
Pharmadrug Inc. Fundamentals Summary
LMLL.F fundamental statistics | |
---|---|
Market cap | US$2.28m |
Earnings (TTM) | -US$9.59m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs LMLL.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
LMLL.F income statement (TTM) | |
---|---|
Revenue | CA$0 |
Cost of Revenue | CA$0 |
Gross Profit | CA$0 |
Other Expenses | CA$13.20m |
Earnings | -CA$13.20m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.13 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | -120.5% |
How did LMLL.F perform over the long term?
See historical performance and comparison